Beauty marketing claims in the US: why sunscreen changes the rules
Marketing language is part of product compliance. Review the claim a reasonable customer will understand, not only the exact sentence the copywriter intended, and give every channel the same approved boundaries.
In this article
Overview
Marketing language is part of product compliance. Review the claim a reasonable customer will understand, not only the exact sentence the copywriter intended, and give every channel the same approved boundaries.
The marketed intended use changes the regulatory path
- Appearance and cleansing
Cosmetic
Marketed to cleanse, beautify, or alter appearance without a drug intended use.
- Appearance-focused language
- Truthful and supported advertising
- Cosmetic labeling obligations
- Treatment or prevention
OTC drug: sunscreen
Marketed to prevent sunburn and subject to the US OTC sunscreen pathway.
- Permitted actives and concentrations
- Finished-product testing
- Drug Facts and drug-side requirements
- Both functions
Drug and cosmetic
A product can sit in both categories and must satisfy the requirements that apply to each.
- One product, two rule sets
- Claims define intended use
- Review before packaging and content
Words can change what the product is
FDA classification depends on intended use. Product names, packaging, websites, creator scripts, search ads, images, testimonials and context can all help establish that use. The language can make a product a drug or both a drug and a cosmetic.
No list of beauty verbs can establish that a claim is acceptable in every context. Have regulatory counsel review the complete set of claims and supporting evidence for the specific formula before approving them.
| Dimension | Cosmetic | OTC drug (sunscreen) |
|---|---|---|
| Intended use | Marketed only to cleanse, beautify, or alter appearance | Says or implies the product treats or prevents disease, or affects the body's structure or function |
| Claim examples | Appearance-focused language about how skin looks | A promise to treat a medical condition |
| Regulatory pathway | May be a cosmetic based on the marketed intended use | Regulated as an OTC drug; without an approved application, must satisfy the current OTC sunscreen monograph, including permitted active ingredients and concentrations and finished-product testing |
| Labeling and advertising obligations | FDA cosmetic labeling requirements apply, including identity, net contents, ingredient and required business information. FTC truthfulness and substantiation standards also apply to advertising | Drug Facts and other drug labeling, drug establishment registration and listing, and drug current good manufacturing practice; FTC advertising standards also apply. A cosmetic–drug combination must meet applicable requirements for both |
FTC looks at the net impression
The FTC's current Health Products Compliance Guidance says advertisers need a reasonable basis for objective claims before dissemination and evaluates the express and implied messages conveyed by the ad as a whole. A small disclaimer cannot reliably reverse a prominent headline, image, testimonial, or demonstration that communicates a broader result; if a significant minority still takes away a misleading claim, the disclosure is not sufficient.
For health-related efficacy or safety claims, the FTC applies its rigorous competent-and-reliable-scientific-evidence standard and encourages review by an independent expert in the relevant field. Ingredient, animal, or in vitro research does not automatically prove a finished-product human claim, and a genuine customer testimonial does not replace substantiation. The evidence should match the formulation, population, use, dose, outcome, and strength of the message.
Sunscreen is the clearest cross-border example
Sunscreen is regulated as an over-the-counter drug in the United States. A product marketed without an approved application must satisfy the current OTC sunscreen monograph and the other drug requirements summarized in the table above.
Do not assume a Korean sunscreen formula can be sold unchanged in the US because its SPF was tested or it is legal in Korea. Compare every active ingredient, concentration, dosage form, test, warning, claim and label element against the current US pathway. The framework can change: FDA's June 9, 2026 final order added bemotrizinol, at concentrations up to 6%, to the OTC sunscreen monograph. It was the first new permitted sunscreen active ingredient since the late 1990s. That change does not automatically make a particular imported finished product compliant or approved.
Build a claims matrix before content production
A claims matrix records each proposed message's exact wording, product and variant, evidence, required qualifier, prohibited implication, owner, approval date and permitted channels. Use this approved record across product pages, marketplace listings, press copy, paid ads, affiliate briefs and customer service responses so each channel describes the product consistently.
- Separate sensory and appearance observations from objective performance, health, safety, or therapeutic claims.
- Record what the finished product evidence supports, not merely what one ingredient is associated with.
- Review the product name, before-and-after image, demonstration, caption, audio, comments, and CTA as one net impression.
- Give creators required disclosures, approved facts, prohibited claims, and an escalation path without scripting away their voice.
- Re-review translated Korean source copy; a literal English translation can create a stronger US claim than the original team intended.
| Proposed asset and message | Potential takeaway and evidence gap | Decision, owner and release condition |
|---|---|---|
| US serum product page and creator brief: 'repairs skin cells' | A structure/function claim, not merely an observation about appearance; ingredient research alone does not establish the finished product's claimed effect or lawful pathway | Hold. The US regulatory specialist must determine classification and the applicable pathway before the brand approves any wording or production brief |
| US moisturizer ad: before-and-after photos presented as a seven-day result | The visual implies a product-caused change. Different lighting, missing use records or evidence from another formula cannot substantiate that takeaway | Hold. The evidence owner supplies the original files, capture conditions, use records and relevant finished-product support; the qualified reviewer evaluates the full ad before release |
Put the review gate before the expensive work
Claims review should happen before packaging is printed, product pages are built, creators are contracted, or ads enter production. Late review creates reprints, rejected listings, unusable content, inventory delays, and inconsistent customer explanations.
Hypothetical example—not client work: a Korean SPF 50 cushion arrives with draft US copy promising 'waterproof protection all day' and creator footage repeating that line. Do not solve this with a smaller disclaimer. FDA treats products labeled with SPF as sunscreen drugs and its labeling rules do not permit 'waterproof' claims; the formula, pathway, finished-product tests, Drug Facts, use language, and water-resistance evidence need specialist review before the packaging or brief is approved.
Use a qualified US regulatory attorney or specialist for classification and claim approval. This article explains the operating problem; it is not legal or regulatory advice and does not determine whether any particular claim or product is compliant.
Sources & further reading
- Is It a Cosmetic, a Drug, or Both?U.S. Food and Drug Administration
- Health Products Compliance GuidanceFederal Trade Commission
- Importing Over-The-Counter DrugsU.S. Food and Drug Administration
- OTC Monograph M020: Sunscreen Drug ProductsU.S. Food and Drug Administration
- FDA expands sunscreen options for the first time in 20 yearsU.S. Food and Drug Administration
- Labeling and effectiveness testing for OTC sunscreen drug productsU.S. Food and Drug Administration
Make the US launch sequence faster and clearer
Dahna helps Korean and US teams connect product truth, positioning, claims-ready messaging, channel requirements, content, creators, and launch timing in one bilingual operating plan. Resolving those dependencies early reduces rework and helps a brand reach useful market feedback faster.
Why consider Dahna for this work?
Dahna brings bilingual Korean and English strategy together with creator, content, and measurement work for brands growing in the US. You can review the people behind the recommendations and the kind of work we propose before starting a conversation.
Founder experience includes prior and contracted roles. Sample deliverables illustrate our approach; they are not client results or a performance promise.
Dahna provides market-entry strategy and marketing execution. Final legal, tax, regulatory, customs, insurance, and freight determinations should be made by qualified specialists in those fields.
